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Abstract
                 Aims We aimed to characterize ethnic differenc es in prevalence, clinical correlates, and outcomes of atrial brillation (AF) in
             heart failure (HF) with preserved and reduced ejection fraction (HFpEF and HFrEF) across Asia.
                Methods and resul ts Among patients with HF prospectively recrui ted across Asian regions using identical protocols5504 11
                      in the Asian Sudden Cardiac Death in Heart Failure study (mean age ± years, % women, % HFrEF), ( %) had61 13 27 83 1383 25
                   AF de ned as a history of AF and/or AF/ utter on baseline electrocard iogram. Clinica l correl ates of AF were similar across eth- 
                  nicities and included older age, prio r stroke, higher NT-proBNP, and larger left atria. Diabetes was associated with lower odds
                 of AF in HFrEF [adjusted odds ratio (AOR) . ,0 79 95% CI 0 66 0 95 0 58 95. – . ] and HFpEF (AOR . , % C I 0 39 0 84. – . ) regardles s of eth-
                nicity. Compared with Chinese ethnicity, Japanes e/Koreans had higher odds of AF in HFrEF (AOR . ,1 76 95% C I 1 40 2 21. – . ), while
             Indians had lower odds in HFrEF (AOR . ,0 18 95% C I % C I0 13 0 24 0 28 95. – . ) and HFpEF (AOR . , 0 16 0 49. – .     ) even after adjust ing for
               clinical covari ates. Interaction between ethnicity and region was observed among Indians, with Southeast Asian Indians having
                  higher odds of AF (AOR . ,3 01 95% CI 1 60 5 67 . – . ) compared with South Asian Indians. AF was associat ed with poorer quality of
                 life and increased risk of year all-cause mo rtality or HF hospitalisation (adjusted hazard ratio . ,1 1 39 95% CI 1 18 1 63. – . ) regard-
  less of ethnicity.
                Conclusions Among patients with HF across Asia, clinical correlates and adverse outcomes associated with AF are similar
                   across ethnicities; however , there are striking ethnic variations in the prevalence of AF that are not accounte d for by known
 risk factors.
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Introduction
         Atrial brillation (AF) is the most common arrhythmia in heart
          failure (HF) and is associated with an increased risk of stroke,
   HF hospitalisation and mortality. 1 2,   Beyond traditional risk
        factors, there is growing evidence of ethnic in uences on
        the prevalence of AF in the context of HF.
3 7–
  A large US
         registry reported a higher prevalence of AF among white HF
      patients compared with bl acks, Hispanics, and Asians 3  ; while
        a prospective Asia Paci c study showed a distinctly lower
      prevalence of AF among Singaporean Asian compared with–
    New Zealand European H F patients. 5   The ethnic differences
        in AF prevalence in HF, while strikin g, remain poorly
understood.
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      Asia is geographically vast, with signi cant heterogeneity
          among patients with HF not only by region but also by
ethnicity.8         It is unknown if ethnic differences in AF prevalence
         and clinical correlates within Asia are present. We aimed to
      characterize ethnic differences in prevalence , clinic al corre-
          lates, and outcomes of AF in HF with preserved and reduced
      ejection fraction (HFpEF and HFrEF) across Asia .
Methods
 Study population
       Participants were identi ed from the Asian Sudden Cardiac
      Death in HF (ASIAN-HF) registry (ClinicalTrials.g ov Identi er:
NCT ).01633398
8
      In brief, ASIAN-HF is a prospective, observa-
       tional, multinational registry of Asian patients with sympto m-
        atic HF. Consecutive patien ts were screened in medical46
        centres across Asian regions (China, Hong Kong, India,11
     Indonesia, Japan, Korea, Malaysia, Philippines, Singapore,
        Taiwan, and Thai land) managing both acute and chronic HF.
        Patients were years and provided written in formed con->18
      sent. Exclusi on crit eria have previously been described.
8
The
        study complied with the Declaratio n of Helsi nki, and ethics
         approvals were obta ined at all sites. All patients enrol led in
         ASIAN-HF had a validated clinical diagnosi s of HF by indepen -
        dent site investigators (based on symptoms , signs, and clini-
      cal decompensation within months). They were6
        categorized as HFrEF and HFpEF based on left ventricular
       ejection fraction % and %, respectively. In addition,< 40 ≥50
      99 5. % of HFpEF patients had echocardiographic evidence
        for diastolic dysfunction [E/e′ ≥ 13, e ′ medial/lateral ms,<9
       left atrial (LA) enlargement, or left ventricular (LV)
hypertrophy].
9
        Recruitment of patients in ASIAN-HF was in two phases,
       through investigation sites which covered a broad spectrum
        of medical, cardiology, and HF specialty units, admitting pa-
        tients with acute HF and conducting outp atient follow-up of
        patients with chronic HF. HFrEF patients were recrui ted be-
       tween October and December ; patien ts with2012 2015
       HFpEF were enrolled betw een September and Decem-2013
 ber .2017
     Data collecti on included patient demographics, clinical
    symptoms, co-morbidities, and medications. Standard
     12-lead electrocardiogram (ECG) and transthor acic echocardi-
         ography were performed in all patients at baseline. Each cen-
    tre performed transthoracic echocardio graphy exams
      according to inte rnationally accepte d guidelines. These as-
        sessments included measurements of LV systolic (EF) and di-
          astolic function (E/e ), as well as LA and LV dimension and′
     volumetric quanti cations. The Cardiovascular Imaging Core
      Laboratory of the National University Health System,
      Singapore, provided oversight and imaging protocol guide-
        lines for qual ity assurance of echocardiograms. Quality of life
        (QoL) assessments were based on the Kansas City Cardiomy-
  opathy Qu estionnaire (KCCQ),
10
    made available in local lan-
       guages in all centres. Quintiles Outc omes, the contract
      research organisation appointed by the AS IAN-HF academic
      executive committee , handled all registry operations and
      data management. ASIAN-HF was an investigator-led study.
 Study de nitions
         Atrial brillation was de ned as a documented history of AF 
        based on medical records and/or presence of AF/a trial utt er
           on baseline -lead ECG. Patients with a history of AF and AF12
         on baseline ECG were classi ed as persistent AF ; history of ‘ ’
         AF without AF on baseline ECG classi ed as paroxysmal AF ; ‘ ’
          AF on baseline ECG without history of AF classi ed as new- ‘
         onset AF ; sinus rhythm on baseline ECG without history of’ 
         AF de ned as sinus rhythm . Only AF and sinus rhythm ‘ ’ ‘ ’ ‘ ’
         were included in this study; other ECG rhythms were ex-
         cluded. Diabetes was de ned as presence of a prior diagno sis
       (fasting plasma glucose mmol/L, random plasma gluco se≥7
        ≥ ≥11 1 1. mmol/L, or HbA C 6 5. %) and/or treatment with anti-
       diabetic medications. Chronic kidney disease was de ned as




       Geographical blocs were de ned in accordance with the
     United Nations Statistics Division subregion classi cation:
       Northeast Asia (South Korea, Japan, Taiwan, Hong Kong ,
        and China), South Asia (India), and Southeas t Asia (Thailand,
     Malaysia, Philippines, Indon esia, and Singapore). Ethnicity
      was de ned as self-reported Chinese, Malay, Indian,
     Japanese/Korean, and indigenous Southe ast Asians (others).
        Patients were routinely fo llowed up every months at6
         each pa rticipating site. The primary outcome of this study is
      composite all-cause mortality or HF hospitalisation within
         1 4973 90year. Follow-up data were avai lable in ( %) patients
         at year ( % lost to follow-up) . An independent outcomes1 10
    committee adjudica ted all outcome events .
 Statistical analysis
       Baseline characteristics were reported as percentages (%) for
        categorical variab les and mean ± standard deviation or me-
       dian (lower quartile, upper quar tile) for continuous variables .
       Differences in baseline characteri stics were assessed with in-
   dependent -test (continuous),t χ
2
   test (categorical), or Mann–
      Whitney test (non-parametri c). Univariable logistic regres-U
         sion was performed for each clinical correlate in its associa-
           tion with AF in each HF type and tested for interaction by
        ethnicity. The association of other ethnicities with AF com-
       pared with Chinese was examine d in multiva riable analyses
      adjusting for demographics, clinical correlates, and medica-
        tions. Chi nese and India ns were further strati ed to assess
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        the association of geography with AF. Because of limited
        availability of LA volume index (LAVI) data, multivariab le anal-
         yses were repeated with the inclusion of LAVI as sensitivity
        analyses. To further investig ate the effects of diabetes, the
       association of diabetic medications with AF was evaluated
     with multiva riable analyses. Inter actions betwe en diabetes
        with body mass index (BMI) and LAVI were in vestigated,
        and strati cation performed if present to evaluat e the associ-
         ation of diabetes with AF in the subgroups. Mean KCCQ
        scores in each domain were adjusted for demographics and
        clinical factors. The association of AF with primary outcome
       was performed by multivariable Cox regressi on analysis in
          the whole cohort of HF, with testing fo r interaction by ethnic -
        ity and HF type. Kaplan Meier surviva l curves of subgroups–
        by ethnicity with and without AF were performed and
          compared by log-rank test. A value of . was consid-P <0 05
       ered statistically signi cant. All statistica l analyses were per -
        formed with SPSS Version (IBM Corporation , NY) or21
   Stata/MP . (StataCorp LP).13 0
Results
        Among patients from the ASIAN-HF registry included in5504
          this study [mean age ± years, % women, BMI61 13 27
   25 5± kg/m 2        , ( %) HFrEF, ( %) HFpEF],4541 83 963 17 1383
         ( %) had AF ( % persisten t AF, % paroxysmal AF, %25 53 34 8
          new-onset AF, % history of AF but missing ECG data). The5
         prevalence of AF was signi cantly lower in HFrEF ( %) than 22
            Table 1 Comparison of baseline characteristics by AF status in HFrEF and HFpEF
 HFrEF HFpEF
         Sinus rhythm AF value Sinus rhythm AF valueP P
         n (%) 3523 (78) 1018 (22) 598 (62) 365 (38)
Characteristics
               Age, years 58 ± 13 65 ± 12 0.001 66 ± 13 73 ± 10 0.001< <
           Female sex 785 (22) 213 (21) 0.356 289 (48) 192 (53) 0.198
                Heart rate, bpm 80 ± 15 79 ± 19 0.366 76 ± 15 78 ± 16 0.062
               SBP, mmHg 119 ± 20 116 ± 19 0.001 134 ± 23 128 ± 22 0.001< <
               DBP, mmHg 73 ± 13 70 ± 13 0.001 73 ± 13 71 ± 13 0.077<
 BMI, kg/m 2              25.1 ± 5.1 24.4 ± 5.0 0.001 27.8 ± 6.2 26.3 ± 6.0 0.001<
            NYHA class III/IV 1118 (34) 342 (37) 0.046 117 (22) 84 (26) 0.266
           NTproBNP*, pg/mL 2852 [1205,8040] 4110 [1915,7731] 0.001 1804 [730,4690] 2808 [1417,5051] 0.081<
Echocardiography
           LVEF, % 27 [22,33] 28 [22,34] 0.022 60 [55,65] 60 [55,66] 0.047
              E/e 22 ± 12 20 ± 10 0.011 17 ± 9 18 ± 7 0.41’
 LVMI, g/m 2              137 ± 47 139 ± 46 0.367 109 ± 38 109 ± 45 0.978
 LAVI, ml/m 2              36 ± 18 55 ± 24 0.001 31 ± 14 52 ± 22 0.001< <
 Medical history
            Ischaemic heart failure 1769 (53) 406 (42) 0.001 203 (38) 101 (31) 0.049<
          Hypertension 1825 (52) 545 (54) 0.319 429 (72) 277 (76) 0.138
          Diabetes 1572 (45) 384 (38) 0.001 313 (52) 159 (44) 0.01<
           Chronic kidney disease 1113 (41) 443(50) 0.001 249 (53) 168 (53) 0.895<
           Prior stroke 187 (5) 119 (12) 0.001 37 (6) 47 (13) 0.001< <
            Peripheral arterial disease 110 (3) 46 (5) 0.03 13 (2) 5 (1) 0.8
            Chronic respiratory disease 274 (8) 89 (9) 0.31 45 (8) 38 (10) 0.12
           Smoking history 1576 (45) 506 (50) 0.004 141 (24) 90 (25) 0.669
           Alcohol history 963 (27) 376 (37) 0.001 84 (14) 73 (20) 0.013<
KCCQ*
            Physical limitation score 75 (50 92) 71 (50 90) 0.08 83 (63 95) 75 (54 92) 0.06– – – –
             Quality of life score 58 (33 75) 58 (33 75) 0.05 75 (50 83) 67 (42 83) 0.04– – – –
            Social limitation score 69 (38 94) 58 (25 91) 0.001 83 (58 100) 75 (50 100) 0.27– – < – –
            Total symptom score 75 (53 92) 75 (50 94) 0.54 81 (58 96) 78 (53 93) 0.08– – – –
            Clinical summary score 72 (54 89) 71 (50 88) 0.21 80 (62 94) 74 (55 91) 0.01– – – –
           Overall score 68 (47 84) 64 (44 83) 0.02 78 (59 91) 72 (53 88) 0.02– – – –
Medications
          ACE-I/ARB 2691 (78) 719 (72) 0.001 367 (69) 202 (59) 0.004<
           Beta blocker 2665 (77) 795 (80) 0.076 357 (67) 247 (73) 0.077
          MRA 2032 (59) 590 (59) 0.818 103 (19) 91 (27) 0.01
          Digoxin 860 (25) 416 (42) 0.001 11 (2) 74 (22) 0.001< <
          Diuretic 2852 (82) 851 (85) 0.033 373 (70) 278 (82) 0.001<
               ACE-I, angiotensin-converting enzyme-inhibitor; ARB, angiotensin II receptor blocker; AF, atrial brillation; BMI, body mass index; DBP,
                diastolic blood pressure; KCCQ, Kansas City Cardiomyopathy questionnaire; LAVI, left atrial volume index; LVEF, left ventricular ejection
                fraction; LVMI, left ventricular mass index; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; SBP, systolic
 blood pressure.
                   Comparison of baseline characteristics among patients with and without AF in HFrEF and HFpEF. Values expressed as mean ± standard
             deviation or percentage (%). * values are expressed as median (lower quartile, upper quartile).
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        HFpEF ( %) ( . ). Baseline chara cteristics of patien ts38 P < 0 001
            by in AF and sinus rhythm by HF type are sh own in Table 1,
        and baseline characteristics of all HF patients strati ed by
   ethnicity in Table S 1       . Patients with AF (compared with sinus
           rhythm) were older and more likely to have a history of prior
        stroke, higher NT-proBNP levels, and larger LA volumes but
         less likely to hav e diabetes and ischemi c heart disease. Mean
          heart rate was similar betw een AF and sinus rhythm in both
        HFrEF and HFpEF, with similar beta blocker usage between
         AF and sinus rhythm but higher digoxin use in AF.
        Japanese/Korean had the largest LA size while Indians had
        the smallest in AF, rega rdless of HF type (Table 2   ). Among pa -
        tients with HFrEF, ( %) had diabete s (mean duration1956 43
          9 7 8 1 98 2 25. ± . years, % type diabetes, % oral hypoglycemic
        agents, % insulin), while ( %) patients with HFpEF8 452 47
           had diabetes (mean duration . ± . years, % type di-12 5 8 9 98 2
      abetes, % oral hypoglycemic agents , % insulin).29 11
     Prevalence of atrial brillation within Asia
        The prevalence of AF by ethnicity and geographical region
     within Asia is shown in Figure 1     . Compared with Chinese, In-
           dians had lower prevalence of AF in both HFpEF ( % vs. %,7 28
           P P< 0 001 17 42. ) and HFrEF ( % vs. %, < 0 001. ), wh ile
       Japanese/Koreans had higher prevalence of AF in HFrEF
         ( % vs. %, . ). Signi cant ethnic differences were47 28 P < 0 001 
          noted in the associat ion with AF by HF type in multivariable
      models adjusted for demographics, clinical correlates, and
 medications (Figure 2      ). Ethnic differences persisted in sensi-
          tivity analyses after further adjustment for LAVI ( = inn 1670
          HFrEF, = in HFpEF) [Indian: adjusted odds ratio (AOR)n 280
        in HFrEF . ,0 25 95% CI 0 17 0 36 0 35 95. – . , AOR in HFpEF . , % C I
      0 18 0 68 3 94 95. – . ; Japanese/Korean: AOR in HFrEF . , % C I
2 81 5 54. – . ].
        Only Chinese and India ns were represented in more than
      one geographical bloc, with striking geographical variations
       present in subgroup analyses. Among Indians,1659 141
         ( %) had AF ( % Southeast Asia vs. % South Asia,8 16 7
          P < 0 001. ). Southeast Asian Indian s were three times as likely
         to have AF compared with South Asian Indians, even after
      adjusting for clinic al covariates (AOR . ,3 01 95% C I 1 60. –
       5 67. ), with no interaction by HF type (pinteraction  = . ).0 15
         Among Chinese, ( %) had AF, with lower preva-1837 577 31 
          lence of AF in Southeast Asia than Northeast Asia ( % vs.29
        34 0 03%, respectively, =P . ). Southe ast Asian Chinese were
         less likely to have AF compared with Northeast Asia n Chinese
      with no interaction by HF type (pinteraction     = . ), but this was0 50
       attenuated after adjusting for differenc es in baseline charac-
     teristics (as above) (AOR . ,0 95 95% C I 0 72 1 27. – . ).
      Clinical correlates of atrial brillation by heart
 failure type
          The clinical correlates of AF in HFrEF and HFpEF were similar
       across ethnicities (no signi cant interaction by ethnic ity, Fig-
ure 2        ). Diabetes was consistently associat ed with lower odds
         of AF in both HFrEF (AOR . ,0 79 95% C I 0 66 0 95. – . ) and HFpEF
     (AOR . ,0 58 95 % CI 0 39 0 84. – . ) in multivariable analys es.
        Adjusting for age, sex, ethnicity, and BMI, anti-diab etic med-
       ications were not associated with AF (Table S 2   ). The associa-
         tion between diabetes and AF was modi ed by BM I in
   patients with HFrEF (p interaction     in HFrEF = . ,0 001 p interaction
         in HFpEF = . ). Among obese (BMI kg/m0 27 ≥ 30
2
 ) patients
         with HFrEF, diabetes was not associated with AF (OR . ,1 39
     95% CI 0 92 2 10. – . ); whereas in non-obes e patients with
         HFrEF, diabetes was associated with lower risk of AF (OR
 0 69 95. , % C I 0 59 0 81. – . ).
       Association of atrial brillation with quality of life
          Patients with AF had poorer QoL based on KCCQ indi ces in
          both HFrEF and HFpEF, with lowest overall score in HFrEF (Ta-
ble 1       ). Adju sted for demographics, clinical confounders and
        education, patients with AF had lower social limitatio n scores
        but similar overall summary scores without HF type interac-
     tions in all domains (Table S3     ). Ethnic variation was noted
    only for social limitation (pinteraction    for ethnic ity = . ),0 009
         such that Indians with AF had lower socia l limitation scores
          (adjusted coef cient . , . ), a difference notβ   12 4 P < 0 001
    observed in the other ethnicities.
      Table 2 Comparison of LAVI by ethnicity
      Chinese Indian Malay Japanese/Korean Others valueP
HFrEF
                AF 56.8 ± 22.1 39.2 ± 19.9 39.6 ± 20.7 63.3 ± 26.9 47.5 ± 17.8 0.001<
                SR 44.8 ± 17.0 28.1 ± 16.6 36.2 ± 16.7 44.2 ± 17.4 36.1 ± 16.9 0.001<
HFpEF
              AF 54.8 ± 22.6 42.4 ± 18.0 41.5 ± 18.2 59.2 ± 21.6 NA 0.02
                SR 36.7 ± 13.5 25.9 ± 13.6 25.6 ± 8.8 39.7 ± 14.8 24.1 ± 6.8 0.001<
               Comparsion of LAVI in patients with and without AF in HFrEF and HFpEF strati ed by ethnicity.
                  AF, atrial brillation; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LAVI, left
         atrial volume indexed by body surface area; SR, sinus rhythm.
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                      Figure 1 Prevalence of atrial brillation by ethnicity and geographical region in within Asia. Prevalence of AF by ethnicity (upper panel) and geograph-
                     ical region (lower panel), classi ed by HFpEF (blue) and HFrEF (red). AF, atrial brillation; HFpEF, heart failure with preserved ejection fraction; HFrEF, 
     heart failure with reduced ejection fraction.
                      Figure 2 Association of clinical correlates with atrial brillation in (A) HFrEF and (B) HFpEF. Multivariable analysis of the association of clinical correlates
                   including ethnicity (Chinese as reference ethnic race) with atrial brillation in (A) HFrEF and (B) HFpEF. ACE-I, angiotensin-converting enzyme inhibitor; 
                   AOR, adjusted odds ratio; ARB, angiotensin receptor-II blocker; BMI, body mass index; COPD, chronic obstructive pulmonary disease; HFpEF, heart fail-
                    ure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; NYHA, New York Heart Association functional class; MRA, min-
  eralocorticoid receptor antagonist.
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     Association of atrial brillation with outcomes
          Over a follow-up period of year, ( %) patients either1 982 20
          died or were hospitalized for HF ( % AF vs. % sinus24 18
         rhythm, . ). AF was asso ciated with increased pri-P < 0 001
      mary outcome (OR . ,1 42 95% C I 1 24 1 63. – . ), witho ut interac-
    tion by HF type (pinteraction     = . ). Similar associations were0 39
         observed for all-cause mortality ( % AF vs. % sinus rhythm,12 9
          P < 0 001 16 11. ) and HF hospitalizations ( % AF vs. % sinus
         rhythm, . ). In separate mu ltivariable model s, AF in-P < 0 001
        creased the risk of all -cause mortality (adjusted HR . ,1 61
     95% CI 1 27 2 06. – . ) and HF hospitalisa tions accountin g for
       death as compet ing risk (adjusted HR . ,1 24 95% CI 1 02. –
       1 52. ), both without interaction by HF type (pinteraction  > 0 05. ).
      Although Kaplan–Meier survival curves by ethnicity appeared
           to show that the association of AF with poor survival was stron-
        ger in Chinese and Indians compared with Malays and
 Japanese/Koreans (Figure 3     ), formal ethnic interaction testing
  was non-signicant (pintera ction    = .0 08). These associations
        among Chinese and Indians persisted even after adjusting for
         age, sex, BMI, NYHA class, enrolment type, HF type, HF
       aetiology, diabetes, hypertension, stroke, and CKD but not
      was present in Malays, Japanese/Koreans, and indigenous
     Southeast Asians (Chinese: AHR .1 51, 95% C I 1.21–1 88. ; Indian:
   AHR . ,2 26 95% CI 1 26. –4.06; Malay : AH R 1.16 95, % CI 0 81. –
     1 65. ; Japanese/Korean: AHR . ,0 93 95% C I 0 58. –1.49; Others:
         AHR 1 44. , 95% C I 0.60–3 50. ). In the total cohort of HF patients,
        AF independently increased the risk of the composite outcome
         of 1 year all-cause mortality or HF hospitalisation in multiple
    models of multivariable adjustments (Table 3).
Discussion
      The prospective multinational ASIAN-HF study provides novel
         ndings on the et hnic differenc es in prevalence of AF among
        patients with HF recruited across Asia using identical proto-
        cols and extends upon previous studies in several important
          ways: (i) it is the rst multinational study on ethnic differ -
           ences and clinic al correl ates of AF in Asia; (ii) by having large
      numbers of adjudicated outcomes and comprehensive QoL
        data; and (iii) having good representation of different ethnic -
         ities in Asia from countries at divergent economic levels. In-
         dians had the lowest prevalence of AF regardless of H F
       type, while Japanese/Korean with HFrEF had the highest
        prevalence of AF. Intere stingly, the associat ion with AF dif-
       fered according to geographical locations among the same
       ethnicity, with Southeast Asian Indians having higher odds
       of AF compared with Nort heast Asian Indian s. Clinical
                      Figure 3 Kaplan Meier survival curves of patients with AF vs. sinus rhythm by ethnicity. Kaplan Meier survival curves of the association of AF with– –
                  primary composite event of HF hospitalisation and all-cause mortality among Chinese, Indians, Malays and Japanese/Koreans with HF, with separation
            of survival curves among Chinese and Indians. AF, atrial brillation; HF, heart failure.
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       correlates and adverse outcomes associated with AF were
  similar across ethnic ities.
    Ethnic variations among Asian-heart failure
patients
      Although the SHOP-PEOPLE study pr eviously rep orted a
         lower prevalence of AF among Asian patients with HF, it
        was not powered to detect differences between the three
       major ethnic races within Singapore and signi cant hetero-
    geneity exists within Asian ethnicities.
5
  The AS IAN-HF study
       offers a unique opportunity for ethnic and interregion al
       comparisons among a large contemporary cohort of Asian
     patients recrui ted simultaneous ly across multiple Asian
       countries using identical study procedures. We report a
          prevalence of % of AF in HF within Asia, consistent with25
       prior observations of % among Asian HF patients.16 42– 11 12,
       Additionally, we found ethnic differences in the prevalence
          of AF within Asia by HF ty pe. In HFrEF, Japanese/Kor ean pa -
         tients had the hi ghest prevalence of AF, while Indians had
          the lowest prevalence of AF in both HFpEF and HFrEF. The
      signi cance of ethnicity was previously demonst rated amon g
      Asian women in the Women s Health Initiative,’
13
while
         South Asians in the United Kingdom had lower AF pre va-
       lence, attributed to inherent genetic di fferences that render
    atria morphologically and physi ologically distinct. 6 14, Ethnic
        variations in our study were independent of traditional AF
       risk factors. Furthe rmore, althou gh ethnic differenc es in LA
       size may precede AF development, ethnic variations notably
      among Japanese/Koreans and Indians in AF prevalence
       persisted in sensitivity analyses after ad justment for LAVI,
       highlighting contributory roles of factors that remain unac-
        counted for. The develop ment of AF is often multifact orial
          and the role of nature versus nurture rema ins of great in-‘ ’
      terest. Although non-shared enviro nmental factors play a
      larger contrib utory role, gen etic and shared enviro nmental
       factors also participate in the pa thogenesis of AF.7 An
       interesting observation from our study was the differential
       AF associations amon g Indian s in geograp hically separate lo-
        cations. Local dietary habits, living conditi ons, and levels of
        physical activity may differ vastly in different regions of
       Asia. Singapor e is an advanced economy with westernized‘ ’
      lifestyle, whereas the Worl d Health Organization classi es
          India as a lower income region. The adoption of the west-‘
         ern lifestyle may explain the tripled odds of AF amon g’
      Southeast Asian Indian s (i.e. Singa pore, Malaysia) compared
        with South Asian Indians (i.e. India). Indee d, the RACE-3
        study highlighted the signi cance of lifestyle factors on AF,
      with exercise and dietary restrictions complementing H F
   medications in AF reduction.
15
   Nonetheless, the lower prev-
        alence of AF among Indian s is consistent with previous
studies 6 14,        and suggests an in trinsic effect of Indian ethnic-
        ity, compared with other ethnicities, on AF. Ethnic variations
          in AF are thus likely a result of complex interaction s be-
       tween genetic and environmental factors that are popula-
       tion speci c, suggesting the need for targeted therapy
  among different populati ons.
  Diabetes-atrial brillation paradox
         Although diabete s is a well-recognized risk factor for AF, the
        paradoxically protective effect of diabetes on AF was re-
     ported in Swedish-HF, SHOP-PEOPLE, and GWTG-H F. 1 5 16, ,
         We now extend this paradoxical association for the rst time
           to a larger cohort across Asia in both HFrEF and HFpEF. The
       exact mechanisms remain unknown, although we have previ-
          ously thought it unlikely to be an effect of collider bias.
17
Sep-
       arately, diabetic medications had been reported to decrease
         the risk of AF. Modulation of electrical and mechanical prop-
        erties of pulmonary veins and atria by dipeptidyl peptidase-4
       inhibitors, inhibition of in ammation and oxidation by met-
       formin and reduct ion of proarrhythmic substrates via in hibi-
      tion of ATP-sensitive potassium channels by glibenclamide
       and tolbuta mide hav e been suggested to confer protective
  bene ts against AF. 18 20–   However, antidiabetic medications
         did not exhibit the same relationship with AF after adjusting
         for patient demographics in our study. The absence of treat-
          ment effect in our study is likely because of different cardiac
        substrates, with HF patien ts more likely to have undergone
       structural and electri cal remod elling, while prior studies were
       in animals or populati ons with largely structurally normal
       hearts. Biological plausibility for the diabetes- AF paradox re-
       mains unp roven, but previous studies have show n diabe tes
         to be associated with inward remodelling effects in the para-
       doxical protection against aortic ane urysms, smaller LV vol-
     umes and more concentric LV remodelling.
21 24–
The
      protection from outward remodelling has been attributed
       to advanced glycation end-prod uct (AGE) cross links, with
        AGE cross link breaker treatmen t leading to LV dilatation.
25
        Given our previous nding of smaller LAVI in diabetes
          Table 3 Association of AF with 1 year primary composite endpoint
     of HF hospitalisation or all-cause mortality
     Hazard ratio 95% CI valueP
    Crude AF 1.42 1.24 1.63 0.001– <
     AF + Age 1.34 1.16 1.54 0.001– <
    Model A 1.31 1.13 1.52 0.001– <
    Model B 1.38 1.18 1.63 0.001– <
        Association of AF with primary composite endpoint of HF
      hospitalisation or all-cause mortality in multivariable adjustment
models.
          Model A: adjusted for age, sex, BMI, NYHA, ethnicity, and enrol-
 ment type.
          Model B: Model A + HF type, HF aetiology, hypertension, diabetes,
   stroke, chronic kidney disease.
         AF, atrial brillation; BMI, body mass index; HF, heart failure;
      NYHA, New York Heart Association functional class
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     regardless of AF or HF subt ype,
5
  diabetic protection against
        atrial outward remodelli ng may plausibly confer a lower risk
          of AF. In non-HF cohorts, BMI was acknowledged as a residual
        confounding factor in the increa sed risk of AF with
diabetes.
26
      An increased association with AF was found
        among obese patients but absent among patients with nor-
 mal weig ht.
27
     Similarly, two Japanese studies, with mean
     BMI within normal ranges ( kg/m22 25–
2
   ) did not demon-
      strate an association between diabetes and AF.28 29, When
        strati ed by BMI, the diabetes-AF paradox was only observ ed
         in non -obese patients with HFrEF, and not in obese patients
         in whom the obesity-associate d highe r odds of AF may have
        masked any diabetes-related lower odds of AF. The exact
        mechanisms by which obesity and diabetes interact in predis-
       posing to AF remains unknown, although interest ingly, the
          Look AH EAD trial did not nd a reduction in AF among
      diabetic patients even with modest weight reduction.
30
It
          should be noted however , that the mean BMI in Look AHEAD
 ( kg/m36
2
        ) was much high er than in ASIAN -HF ( kg/m25
2
),
           and the modest weight loss of % in Look AHEAD might have6
       been insuf cient to reduce the risk of AF.
     Association of atrial brillation with outcomes
           AF portends a poorer prognosis in HF. We found a direct as-
         sociation of AF with death or HF hospitalisation regardless of
      HF type, consistent with the Swedish-HF registry.1  Data on
          ethnic differenc es in outcomes with AF in the context of HF
       are con icting. H igher in-hospital mortality in black compared
        with white, Hispanic, and Asian-American HF patients with AF
 were noted,
3
      but ethnic differenc es were not obser ved be-
        tween black and white patients in the GWTG-HF registry
4
or
       Asian and white patients in the Asia-Paci c SHOP-PEOPLE
study.
5
     Although ethnic inte ractions with primary outcome
       were not statistically signi cant, the distinct separation in
        Kaplan Meier surviva l curves by AF among Chines e and In-–
       dians persisted even after adjusting for demographics and
     clinical co-morbidities. Exact mechanisms underlying these
      observations are uncertain and deserve further stud y.
Limitations
         We acknowledge the potential of selection bias from site se-
         lection and variations in patient willingness to participate in a
        prospective registry . Site selection in ASIAN -HF was based on
        the size and geographical location within the country, patient
      population, and availability of expertis e in echocardiogr aphy.
        Efforts were made to ensure protocol standardisation and ad-
    herence, including region-speci c language translations,
       on-site investigator training and regula r monitoring, and cen-
       tralized databas e manag ement in order to maintain quality
       data and minimize missing data. Ethnicity was self-reported ,
        with the potential for misclassi cation. The number of indig-
         enous Southeast Asian patients with HFpEF was too small to
       allow for meaningf ul comparisons. We recogniz e the differ-
       ences in healthcare systems and cultural barriers to
       healthcare access within Asia, which may potentially affe ct
            the AF and HF burden in our study. Duration of AF and the
         incidence of AF during the course of follow-up were unavail-
        able. Analyses of AF prevalence were cross-sectional and do
      not allow ascertain ment of temporal relationships between
        AF and other clinical factors. Moreover, patients with asymp-
       tomatic paroxys mal AF may have been undetected, althou gh
        the inclusion of these patients will unli kely attenuate the
       strong relationships with AF seen in our study.
Conclusions
         Among patients with HF across Asia, clinical correlates and ad-
        verse outcomes associated with AF are similar across ethnicities;
        however, there are striking ethnic variations in the prevalence
          of AF that are not accounted for by known risk factors.
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